title: Thalidomide-derived immunomodulatory drugs as therapeutic agents.
abstract: Thalidomide, a drug originally used to treat morning sickness, was removed from the market place in the early 1960s after it was found to cause serious congenital birth defects. However, thalidomide has recently been investigated in a new light following its activity in a number of chronic diseases. Moreover, like thalidomide itself, its second-generation immunomodulatory drug (IMiD) analogues have been shown to act as powerful anticancer agents and are clearly active in the treatment of patients with relapsed multiple myeloma. These new drugs, in particular the second-generation IMiDs, lenalidomide (CC-5013, REVLIMID; Celgene Corp., NJ, USA) and CC-4047 (ACTIMID; Celgene Corp.), offer improvements over thalidomide (a first-generation IMiD) in terms of efficacy and safety in human studies. The key to the therapeutic potential of IMiDs lies in the fact that the drugs have multiple mechanisms of action, which may produce both anti-inflammatory and antitumour effects. These effects are probably contextual, depending both on the cell type and the stimulus involved. Mechanisms associated with IMiD activity include TNF-alpha-inhibitory, T cell costimulatory and antiangiogenic activities. Studies of the mechanisms of action of these drugs are ongoing and will facilitate the continued development of this class of compound in a number of diseases.
authors.affiliation: St George's Hospital Medical School, Division of Oncology, Department of Cellular & Molecular Medicine, Cranmer Terrace, London, SW17 0RE, UK. cgalusti@sghms.ac.uk
authors.forename: Christine
authors.initials: C
authors.lastname: Galustian
authors.forename: Marie-Christine
authors.initials: MC
authors.lastname: Labarthe
authors.forename: J Blake
authors.initials: JB
authors.lastname: Bartlett
authors.forename: Angus G
authors.initials: AG
authors.lastname: Dalgleish
mesh_terms: D000893:Anti-Inflammatory Agents / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D006801:Humans; D007155:Immunologic Factors / Q000737:chemistry* / Q000276:immunology / Q000627:therapeutic use*; D013792:Thalidomide / Q000737:chemistry* / Q000276:immunology / Q000627:therapeutic use*
chemical_list: D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D007155:Immunologic Factors; D013792:Thalidomide